Last updated on March 2018

A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder


Brief description of study

The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).

Detailed Study Description

This is a Phase 2a randomized (study drug assigned by chance), double-blind (neither the Investigator nor the participants know about the study intervention), placebo-controlled, parallel-group, multi-center study of JNJ-42165279 in participants with social anxiety disorder. Participants will receive 25 milligram (mg) JNJ-42165279 or matching placebo orally once-daily from Day 1 up to 12 weeks. Participants will primarily be assessed for the change from baseline in Liebowitz Social Anxiety Scale (LSAS) at Week 12. Safety will be monitored throughout the study.

Clinical Study Identifier: NCT02432703

Find a site near you

Start Over

APG Research, LLC

Orlando, FL United States
  Connect »

Massachusetts General

Boston, MA United States
  Connect »

Clinilabs

New York, NY United States
  Connect »

Finger Lakes Clinical Research

Rochester, NY United States
  Connect »

Richmond Behavioural Associates

Staten Island, NY United States
  Connect »

PRA Health Sciences

Salt Lake City, UT United States
  Connect »